Plasma ALZpath p‐tau217 for the identification of amyloid and tau positivity
Nicholas J. Ashton,Guglielmo Di Molfetta,Wagner Scheeren Brum,Andrea Lessa Benedet,Burak Arslan,Erin M. Jonaitis,Rebecca E Langhough,Karly Alex Cody,Tobey J Betthauser,Kirk J. Hogan,Bradley T. Christian,Nesrine Rahmouni,Jenna Stevenson,Laia Montoliu‐Gaya,Juan Lantero Rodriguez,Gallen Triana‐Baltzer,Hartmuth C. Kolb,Jeroen Vanbrabant,Erik Stoops,Andreas Jeromin,Pedro Rosa‐Neto,Sterling C Johnson,Kaj Blennow,Henrik Zetterberg
DOI: https://doi.org/10.1002/alz.079892
2023-12-01
Abstract:Abstract Background In the last 5 years, immunoassays for the quantification of phosphorylated tau (p‐tau) in blood have proven to accurately identify Alzheimer’s disease (AD) pathology with important implications for primary care management and therapeutic trials. Comparisons of p‐tau epitopes (p‐tau181, p‐tau217, p‐tau231) show small differences in diagnostic accuracy, however, often p‐tau217 is preferred, citing its larger fold‐change in symptomatic patients and lower rate of false positives in amyloid‐negative individuals. This study describes the performance of a novel Single molecule array (Simoa) for p‐tau217 (p‐tau217 ALZpath ) Method We included 355 participants from Translational Biomarkers in Aging and Dementia (TRIAD) participants, which was representative of the AD continuum. Further, 425 cognitively unimpaired individuals, with longitudinal plasma measures (≤8 years), were included from Wisconsin Registry for Alzheimer’s Prevention (WRAP). All plasma samples were measured for ALZpath p‐tau217 ALZpath , a validated Simoa assay at the University of Gothenburg, Sweden. In TRIAD, amyloid positivity (A+) was defined as [ 18 F]AZD‐4694 SUVR >1.5 or CSF Aβ42/40 1.16. 18 F‐MK‐6240 determined tau status (T+) both cohorts (TRIAD, >1.24 SUVR; WRAP, >1.3). Result In TRIAD, p‐tau217 ALZpath determined A+ (AUC = 0.957, 0.935‐978) and T+ (AUC = 0.952, 0.929–0.976) individuals with high accuracy. A sensitivity analysis, including only participants with imaging (amyloid and tau) and CSF biomarkers (p‐tau181, p‐tau205, p‐tau217, Aβ42/40), p‐tau217 ALZpath demonstrated equivalent accuracies in determining A+ (Figure 1A) and T+ (Figure 1B) than these high‐performing modalities. In addition, plasma p‐tau217 AlzPATH demonstrated a good accuracy to identify T+ from all A+ participants (AUC = 0.839, 0.767‐910). Concentration cut‐points derived in WRAP to identify A+ (>0.676 pg/mL; PPV = 87.2%) and A– ( 0.676 pg/mL, PPV = 98.8%; <0.235 pg/mL, NPV = 95.1%. In WRAP, longitudinal analysis (Figure 2) demonstrated that over 8‐years, p‐tau217 AlzPATH increased only in A+ individuals and more steeply in A+T+ participants (β estimate = 0.1 pg/mL per year; P <0.0001) compared to A+T‐ (β estimate = 0.022 pg/mL per year, P = 0.0008). Conclusion The novel p‐tau217 ALZpath immunoassay demonstrates high accuracy to determine amyloid and tau pathology across all stages of AD continuum. Clinical cut‐points to identify A+ or A– with high PPV and NPV are directly transferable across cohorts.
clinical neurology